MIT

MaRS Innovation, GlaxoSmithKline partner to accelerate translational research

Tuesday, May 31, 2011 03:37 PM

MaRS Innovation (MI) and GlaxoSmithKline (GSK) have announced a new development fund—the GSK-MaRS Innovation Fund—to support and fast-track the commercialization of some of Canada’s most promising translational research coming from 16 leading academic health sciences centers, hospitals and universities derived from the MI membership.

More... »

Bayer CEO considers merger only if stars are aligned

Thursday, May 5, 2011 12:40 PM

German-based Bayer is open to a “merger of equals” that would enhance its health-care unit without paying a premium for an acquisition, says Bayer’s chief executive officer Marijn Dekkers, according to a Bloomberg report.

More... »

BioClinica inks seven with Trident IWR

Monday, April 18, 2011 11:55 AM

Pennsylvania-based BioClinica, a provider of clinical trial management solutions, has been selected by seven new clients for the use of BioClinica’s Trident IWR (interactive web response) to help build and deploy clinical trials without the need for programming.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

GSK to sell OTC brands

Friday, April 15, 2011 12:30 PM

Reorganization of GlaxoSmithKline's consumer healthcare business will result in the divestment of $800 million worth of over-the-counter products, including its controversial weight loss drug Alli, according to Pharma Times.

More... »

Austria's F-star raises $22 million

Thursday, April 14, 2011 11:31 AM

F-star, an Austrian biotechnology firm, has raised $22 million in a financing led by SR One, the corporate venture capital arm of GlaxoSmithKline, according to Pharma Times.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

Actelion board nominates two

Wednesday, April 6, 2011 12:40 PM

Actelion has nominated two pharmaceutical executives, including ex-GlaxoSmithKline boss Jean-Pierre Garnier, to join the board after shareholder Elliott Advisors repeated calls for changes in management and strategy, according to Pharma Times.

More... »

Dainippon Sumitomo Pharma and Intercept Pharmaceuticals partner

Friday, April 1, 2011 11:47 AM

Japan-based Dainippon Sumitomo Pharma (DSP) and U.S.-based Intercept Pharmaceuticals announced an exclusive licensing agreement for the development and commercialization of Intercept's first-in-class FXR agonist obeticholic acid (OCA, also known as INT-747), according to FierceBiotech. DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, initially focusing on primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).

More... »

AltheRx acquires Solabegron from GSK

Tuesday, March 29, 2011 12:39 PM

AltheRx, a privately-held clinical development company, has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in phase II clinical programs for the treatment of overactive bladder (OAB) in women and irritable bowel syndrome (IBS). Solabegron also demonstrated a favorable tolerability profile across all phase II studies.

More... »